0001209191-16-132076.txt : 20160707
0001209191-16-132076.hdr.sgml : 20160707
20160707184609
ACCESSION NUMBER: 0001209191-16-132076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160705
FILED AS OF DATE: 20160707
DATE AS OF CHANGE: 20160707
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tobira Therapeutics, Inc.
CENTRAL INDEX KEY: 0001311596
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030422069
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 701 GATEWAY BLVD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-741-6625
MAIL ADDRESS:
STREET 1: 701 GATEWAY BLVD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Tibira Therapeutics, Inc.
DATE OF NAME CHANGE: 20150506
FORMER COMPANY:
FORMER CONFORMED NAME: Regado Biosciences Inc
DATE OF NAME CHANGE: 20041215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35953
FILM NUMBER: 161757469
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-07-05
0
0001311596
Tobira Therapeutics, Inc.
TBRA
0001388325
Novo A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
Common Stock
2016-07-05
4
S
0
10400
12.5682
D
2016691
D
Common Stock
2016-07-06
4
S
0
59850
12.2017
D
1956841
D
Common Stock
2016-07-07
4
S
0
21869
12.033
D
1934972
D
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.50 to $12.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.12 to $12.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Novo A/S is a Danish limited liability company. The board of directors of Novo A/S (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Thomas Dyrberg, Chief Executive Officer, Novo A/S
2016-07-07